Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.
about
Hepatitis C virus protease inhibitor-resistance mutations: our experience and reviewPlatelet count and sustained virological response in hepatitis C treatment.No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCVRelationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysisIs the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatmentIL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase.Individualization of chronic hepatitis C treatment according to the host characteristics.Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.Treatment of hepatitis C virus infection in the future.Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin.Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCVPharmacogenetics of ribavirin-induced anemia in HCV patients.IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens.
P2860
Q24628717-7167A50A-F8F3-4F42-A231-241572F3AC00Q33407719-0C74CD0E-FB84-466B-B372-CC58D20F4A5BQ35069533-603B45E5-8097-41EF-A28E-20D5D155A880Q35799774-AE65B102-10C7-4038-81B8-975B718958DDQ35947900-65E8D379-4385-435D-AC3C-9C5C8F51D78BQ36953126-B27FE62F-5FFC-4E08-AE03-8979D5E9C7ABQ37358287-4B9BEDF9-D516-4230-87DD-B7EB4E080F99Q37654502-220435E6-1964-4283-9ACC-A2AE40CCB45DQ38136078-DDD59CA5-7026-496F-98D3-34D67A8F0409Q38985488-4E3A3C88-BDA6-4553-A716-950452D05769Q39436509-6D1DE550-F5E2-460C-A2C8-2AE717891E96Q40209039-5378A84E-7329-4DFA-A54A-31DD7623F34FQ40228687-54A10848-9BAD-48EB-8E39-96AAE8937D49Q40650428-D2DBB3EB-BB4C-49E5-B69A-4FF560DF338EQ41576433-6FFA6AA5-EB38-499E-9F32-04D48185202F
P2860
Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Roles of ITPA and IL28B genoty ...... peginterferon plus ribavirin.
@ast
Roles of ITPA and IL28B genoty ...... peginterferon plus ribavirin.
@en
type
label
Roles of ITPA and IL28B genoty ...... peginterferon plus ribavirin.
@ast
Roles of ITPA and IL28B genoty ...... peginterferon plus ribavirin.
@en
prefLabel
Roles of ITPA and IL28B genoty ...... peginterferon plus ribavirin.
@ast
Roles of ITPA and IL28B genoty ...... peginterferon plus ribavirin.
@en
P2093
P2860
P356
P1433
P1476
Roles of ITPA and IL28B genoty ...... peginterferon plus ribavirin.
@en
P2093
Fumio Imazeki
Keiichi Fujiwara
Makoto Arai
Osamu Yokosuka
Shingo Nakamoto
Tatsuo Kanda
Tatsuo Miyamura
P2860
P304
P356
10.3390/V4081264
P577
2012-08-14T00:00:00Z